Emerging therapeutic options for the management of hepatitis C infection

Until recently the traditional treatment for hepatitis C infection included pegylated interferon and ribavirin combination therapy.The sustained virological response(SVR)seen with this combination is poor and requires lengthy treatment to achieve.Additionally,significant side effects and numerous co...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastroenterology : WJG Vol. 20; no. 23; pp. 7079 - 7088
Main Author Thompson, J Richard
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Inc 21.06.2014
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Until recently the traditional treatment for hepatitis C infection included pegylated interferon and ribavirin combination therapy.The sustained virological response(SVR)seen with this combination is poor and requires lengthy treatment to achieve.Additionally,significant side effects and numerous contraindications prevented many patients from being successfully treated with this therapy.In 2011,two new protease inhibitors,telaprevir and boceprevir,were approved for use with pegylated interferon and ribavirin in the United States by the United States Food and Drug Administration.These agents have significantly improved SVR rates;however significant problems with toxicity remain including severe skin rash and neutropenia.There are a wide range of compounds in late stage development for the future treatment of hepatitis C that exploit many different mechanisms of viral inhibition.Some of these compounds include additional protease inhibitors,like telaprevir and boceprevir,as well as inhibitors of other nonstructural proteins in the viral genome such as NS5A and NS5B,and compounds that target host proteins within the virus.Some of these agents are being developed for oral administration once daily and various combinations are being assessed for use without the need for pegylated interferon and ribavirin.This paper reviews agents in late phase development that may be commercially available within 1-2 years.
Bibliography:J Richard Thompson;Department of Pharmacy Practice,One University Park Drive,Lipscomb University College of Pharmacy,Nashville,TN 37204,United States
Correspondence to: J Richard Thompson, PharmD, MBA, BCPS, Department of Pharmacy Practice, One University Park Drive, Lipscomb University College of Pharmacy, Nashville, TN 37204, United States. richard.thompson@lipscomb.edu
Telephone: +1-615-9667172 Fax: +1-615-9667163
Author contributions: Thompson JR reviewed the literature and wrote the entire content for this manuscript.
ISSN:1007-9327
2219-2840
DOI:10.3748/wjg.v20.i23.7079